news

Tinostamustine granted Orphan Drug Designation by European Commission

2
SHARES

Tinostamustine has been granted Orphan Drug Designation by the European Commission to the treatment of T-cell prolymphocytic leukaemia (T-PLL).

Destruction of cancer cell with Orphan Drug

The European Commission (EC) has now adopted the recommendation to grant Orphan Drug Designation (ODD) to tinostamustine. The recommendation came from the European Medicines Agency‘s (EMA) Committee for Orphan Medicinal Products. The drug is produced by Mundipharma, which announced the update.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Tinostamustine is an alkylating histone-deacetylase inhibiting molecule, developed for the treatment of T-cell prolymphocytic leukaemia (T-PLL). T-PLL is an extremely rare and typically aggressive leukaemia.

Pre-clinical studies have shown that tinostamustine has the potential to improve access to the DNA strands within cancer cells, break them and counteract damage repair. The pre-clinical data also suggest that these complementary and simultaneous modes of action have the potential to overcome resistance towards some other cancer treatments.

Brian Sheehan, Chief Scientific Officer at Mundipharma Research, said: “ODD is an important milestone in the development of tinostamustine, which is currently in early phase clinical trials. We are proud of our commitment to helping patients with rare and difficult-to-treat cancers, such as T-PLL, where therapeutic options are so limited and patients have a clear need for new therapies.”

The EC decision adopting the EMA opinion follows that of the US Food and Drug Administration (FDA), which granted tinostamustine ODD status for the treatment of T-PLL in March 2019. 

Share via
Share via